Request a Demo

Fill in the form below to see the alva Reputation Intelligence Platform in action, and to see how we can help you.

Blog

Posts in tag pharma

CEO blog: Theranos – Falling for the “snake oil salesman”

Published the 21 March, 2018
Theranos scandal: Falling for the “snake oil salesman”

The ongoing fallout of Theranos is a timely reminder that in an age of fake news, clickbait and startup hype, responsibility for these incidents does not lie with the ambitious entrepreneur alone. alva’s CEO reviews this incident and argues that it is also the responsibility of the media and investors to ask the difficult questions […]

Read more

The new stakeholder landscape of digital healthcare

Published the 19 February, 2018
Digital healthcare considerations for corporate affairs and communications

As technology-enabled care becomes inevitable, pharmaceutical companies now need to redefine their relationships with external stakeholders. A key shift will be with “end-user” stakeholders, particularly with patients and, perhaps to a lesser degree, healthcare professionals (HCPs). It should be the role of the Corporate Affairs leader to understand and interpret these changing conversations, expectations and […]

Read more

Who are the most visible global Pharma CEOs?

Published the 07 September, 2017

Ahead of alva’s annual Pharmaceutical CEO report, we reviewed the most visible CEOs in the global pharma sector over the past 12 months. We analysed millions of pieces of global content, across all media channels, to discover which senior pharma figures were featuring most often. Image 1: Most visible Pharma CEOs   Kenneth c. Frazier […]

Read more

Building stakeholder understanding in Pharma: combining internal and external data

Published the 23 March, 2017
Pharmaceutical KPIs

The regulations surrounding the pharma industry can sometimes mean it is difficult to get detailed insight on the key issues driving perceptions of the sector. In this piece we look at how companies can get a more in-depth view of their stakeholders by reviewing some scenarios we regularly encounter. At alva, we help pharma companies to […]

Read more

How big a risk is drug pricing to pharmaceuticals?

Published the 21 July, 2016

The health secretary Jeremy Hunt has asked the competition watchdog to investigate accusations that drug companies are “exploiting” the NHS to raise their prices. The claim is that the use of loopholes has resulted in a price rise of over 1,000% for 32 drugs over the past 5 years. This follows concern from within the […]

Read more

Brexit: is the reputation of pharmaceutical companies at risk?

Published the 07 April, 2016

On 20 February, UK prime minister David Cameron announced that the EU referendum deciding if Britain should remain in the European Union will be held on 23 June 2016. This announcement has triggered concerns for the pharmaceutical sector, with several industry commentators stating that continued EU membership is in the best interest of the UK’s […]

Read more

What are the reputational risks associated with clinical trial transparency in the public sphere?

Published the 15 January, 2016

Calls for transparency in the pharmaceutical industry have grown in recent years, focusing on issues including pricing, access to medicine and how companies report finances. While these calls for transparency have come from healthcare professionals, investors and regulatory bodies, the cause for clinical trial transparency has had a vocal leader in Ben Goldacre. Ben Goldacre […]

Read more

R&D innovation – a reputation differentiator for pharma

Published the 17 November, 2015

AstraZeneca, GSK and Merck were the top three pharmaceutical companies for R&D innovation in alva’s reputation analysis These companies had the best reputations for R&D innovation, emphasising “pioneering” or first-in-class innovation and highlighting initiatives aimed at improving health in the developing world All five companies trended downwards over the period, and it remains to be […]

Read more

Which are the top 3 pharma companies for efficient business?

Published the 14 August, 2015

In recent months, the pharmaceutical and biotechnology industries have seen a drive for streamlined business, with a sharp rise in M&A activity, internal restructuring and new headquarters and facilities. While the investor community has tended to view these changes positively when linked to improved financial performance, employees and local politicians reacted negatively when jobs were […]

Read more